Literature DB >> 29644570

Psoriatic disease treatment nowadays: unmet needs among the "jungle of biologic drugs and small molecules".

Matteo Megna1, Anna Balato2, Maddalena Napolitano3, Lucia Gallo1, Francesco Caso4, Luisa Costa4, Nicola Balato1, Raffaele Scarpa5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29644570     DOI： 10.1007/s10067-018-4090-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  30 in total

1.  Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.

Authors:  K Papp; D Thaçi; K Reich; E Riedl; R G Langley; J G Krueger; A B Gottlieb; H Nakagawa; E P Bowman; A Mehta; Q Li; Y Zhou; R Shames
Journal:  Br J Dermatol       Date:  2015-10-15       Impact factor: 9.302

2.  Vascular perfusion kinetics by contrast-enhanced ultrasound are related to synovial microvascularity in the joints of psoriatic arthritis.

Authors:  Ugo Fiocco; Roberto Stramare; Alessandro Coran; Enrico Grisan; Elena Scagliori; Francesco Caso; Luisa Costa; Francesca Lunardi; Francesca Oliviero; Fulvia Chieco Bianchi; Anna Scanu; Veronica Martini; Daniele Boso; Valeria Beltrame; Maristella Vezzù; Luisella Cozzi; Raffaele Scarpa; David Sacerdoti; Leonardo Punzi; Andrea Doria; Fiorella Calabrese; Leopoldo Rubaltelli
Journal:  Clin Rheumatol       Date:  2015-02-14       Impact factor: 2.980

3.  Psoriatic Disease 10 Years Later.

Authors:  Raffaele Scarpa; Francesco Caso; Luisa Costa; Rosario Peluso; Antonio Del Puente; Ignazio Olivieri
Journal:  J Rheumatol       Date:  2017-09       Impact factor: 4.666

Review 4.  Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study.

Authors:  Francesco Caso; Antonio Del Puente; Francesca Oliviero; Rosario Peluso; Nicolò Girolimetto; Paolo Bottiglieri; Francesca Foglia; Carolina Benigno; Marco Tasso; Leonardo Punzi; Raffaele Scarpa; Luisa Costa
Journal:  Clin Rheumatol       Date:  2018-01-08       Impact factor: 2.980

5.  JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis.

Authors:  Ugo Fiocco; Benedetta Accordi; Veronica Martini; Francesca Oliviero; Monica Facco; Anna Cabrelle; Lucia Piva; Beatrice Molena; Francesco Caso; Luisa Costa; Anna Scanu; Elisa Pagnin; Mariangela Atteno; Raffaele Scarpa; Giuseppe Basso; Gianpietro Semenzato; Leonardo Punzi; Andrea Doria; Jean-Michel Dayer
Journal:  Immunol Res       Date:  2014-01       Impact factor: 2.829

Review 6.  Psoriasis: to treat or to manage?

Authors:  Ulrich Mrowietz; Kirsten Steinz; Sascha Gerdes
Journal:  Exp Dermatol       Date:  2014-08-02       Impact factor: 3.960

Review 7.  Guselkumab for the treatment of psoriasis.

Authors:  Matteo Megna; Anna Balato; Annunziata Raimondo; Nicola Balato
Journal:  Expert Opin Biol Ther       Date:  2018-03-03       Impact factor: 4.388

8.  Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.

Authors:  Hidemi Nakagawa; Hiroaki Niiro; Kenji Ootaki
Journal:  J Dermatol Sci       Date:  2015-10-24       Impact factor: 4.563

Review 9.  Psoriatic arthritis: tissue-directed inflammation?

Authors:  Giacomo Cafaro; Iain B McInnes
Journal:  Clin Rheumatol       Date:  2018-02-23       Impact factor: 2.980

Review 10.  Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.

Authors:  Francesco Caso; Ennio Lubrano; Antonio Del Puente; Paolo Caso; Rosario Peluso; Francesca Foglia; Carolina Benigno; Nicolò Girolimetto; Paolo Bottiglieri; Raffaele Scarpa; Luisa Costa
Journal:  Expert Rev Clin Immunol       Date:  2015-12-09       Impact factor: 4.473
View more
  8 in total

Review 1.  Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge.

Authors:  Angelo Ruggiero; Luca Potestio; Elisa Camela; Gabriella Fabbrocini; Matteo Megna
Journal:  Psoriasis (Auckl)       Date:  2022-06-08

2.  Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.

Authors:  Matteo Megna; Cataldo Patruno; Maria Rita Bongiorno; Alessio Gambardella; Claudio Guarneri; Paolo Romita; Annunziata Raimondo; Francesco Loconsole; Gabriella Fabbrocini
Journal:  Clin Drug Investig       Date:  2022-05-28       Impact factor: 3.580

3.  Retention rates and identification of factors associated with anti-TNFα, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting.

Authors:  Luca Navarini; Luisa Costa; Marco Tasso; Maria Sole Chimenti; Damiano Currado; Giulia Lavinia Fonti; Massimo Ciccozzi; Domenico Paolo Emanuele Margiotta; Carolina Benigno; Erica De Martino; Roberto Perricone; Antonella Afeltra; Raffaele Scarpa; Francesco Caso
Journal:  Clin Rheumatol       Date:  2020-03-18       Impact factor: 2.980

Review 4.  Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management.

Authors:  Francesco Caso; Marco Tasso; Maria Sole Chimenti; Luca Navarini; Carlo Perricone; Nicolò Girolimetto; Rosario Peluso; Antonio Del Puente; Antonella Afeltra; Roberto Perricone; Leonardo Punzi; Raffaele Scarpa; Luisa Costa
Journal:  Drugs Aging       Date:  2019-10       Impact factor: 3.923

Review 5.  Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative.

Authors:  Gabriele De Marco; Anna Berekméri; Laura C Coates; Sayam Dubash; Jenny Emmel; Dafna D Gladman; Ennio Lubrano; Dennis G McGonagle; Farrouq Mahmood; Antonio Marchesoni; Laura Mason; Alexis Ogdie; Miriam Wittmann; Philip S Helliwell; Helena Marzo-Ortega
Journal:  Rheumatol Adv Pract       Date:  2020-07-11

6.  Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.

Authors:  Angelo Ruggiero; Gabriella Fabbrocini; Eleonora Cinelli; Matteo Megna
Journal:  Dermatol Ther       Date:  2021-11-30       Impact factor: 3.858

7.  Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.

Authors:  Georgios Kokolakis; Kasper Vadstrup; Jes B Hansen; Jose Manuel Carrascosa
Journal:  Dermatology       Date:  2021-11-25       Impact factor: 5.197

8.  Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study.

Authors:  Matteo Megna; Luca Potestio; Angelo Ruggiero; Elisa Camela; Gabriella Fabbrocini
Journal:  Dermatol Ther       Date:  2022-04-26       Impact factor: 3.858
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.